Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all synonyms
Select your origin of interest
BTK-inhibitor ibrutinib and FK866 resulted in a significant and synergistic anti-Waldenstrom macroglobulinemia cell death, regardless of MYD88 (show MYD88 Proteins) and CXCR4 (show CXCR4 Proteins) mutational status.
Strong synergism was observed with pimasertib combined with the PI3K (show PIK3CA Proteins) inhibitor idelalisib and the BTK inhibitor ibrutinib in cell lines derived from diffuse large B-cell lymphoma (DLBCL) and mantle cell lymphoma. The data were confirmed in an in vivo experiment treating DLBCL xenografts with pimasertib and ibrutinib.
these data show that BTK is a critical NLRP3 (show NLRP3 Proteins) inflammasome regulator
Resistant BTK mutants reconstituted B cell receptor-triggered chemokine (show CCL1 Proteins) secretion in the presence of corresponding inhibitors, demonstrating that BTK activity is connected with cell-intrinsic functions of malignant B cells with importance for their dialogue with the micro-environment.
Bone marrow mesenchymal stem cells could increase myeloma stemness via activation of the BTK signal pathway.
the results show that the interaction between BTK and ANKRD54 is highly selective, since it was also identified in a screen using human SH3-domainome. A novel finding is that BTK not only binds to ANKRD54, but stands out as the preferred interactor, being highly dominant over all other human SH3-domains.
this study elucidated mechanisms of BCL2 (show BCL2 Proteins) overexpression and association of this survival pathway with the BCR (show BCR Proteins)/BTK signaling pathway in MCL (show FH Proteins), and revealed the role of BTK in noncanonical NF-kappaB (show NFKB1 Proteins) activation, which also promotes cancer cell survival.
BTK, via p65BTK expression, is a novel and powerful oncogene (show RAB1A Proteins) acting downstream of the RAS/MAPK (show MAPK1 Proteins) pathway and suggest that its targeting may be a promising therapeutic approach.
We conclude that despite being involved in oncogenic signals in blood malignancies, BTK has antineoplastic properties in other contexts, such as the enhancement of p53 (show TP53 Proteins)'s tumor suppressor responses
Inhibition of Btk by inhalation of aerosolized RN983 may be effective as a stand-alone asthma therapy.
Rictor positively regulates B cell receptor signaling via up-regulating Btk and down-regulating SH2-containing inositol phosphatase (show INPP5D Proteins)
The pre-B-cell receptor (pre-BCR (show BCR Proteins)) signaling molecules BLNK (show BLNK Proteins), BTK and BANK1 (show BANK1 Proteins) were positively regulated by the ZFP521 gene, leading to enhancement of the pre-BCR (show BCR Proteins) signaling pathway.
these data indicate that in mature B cells, Tec and Btk may compete for activation of the Akt signaling pathway, whereby the activating capacity of Btk is limited by the presence of Tec kinase.
these data demonstrate that enhanced BTK signaling in B cells can establish a T cell-driven proinflammatory loop resulting in autoimmune pathology, making BTK inhibition an attractive therapeutic strategy
Btk and NLRP3 (show NLRP3 Proteins) co-regulate platelet activation, aggregation, and in vitro thrombus formation.The NLRP3 (show NLRP3 Proteins) inflammasome is upregulated in activated platelets.
Btk inhibition ameliorated hepatocellular injury in a well-established model of liver partial warm ischemia and in situ reperfusion.
report that BTK is expressed by murine and human MDSCs, and that ibrutinib is able to inhibit BTK phosphorylation in these cells
ITK (show ITK Proteins) and BTK regulate thermal homeostasis during septic response through mast cell function in mice.
inositol hexakisphosphate (IP6 (show GPRIN2 Proteins)), a soluble signaling molecule found in both animal and plant cells, also activates Btk.
The protein encoded by this gene plays a crucial role in B-cell development. Mutations in this gene cause X-linked agammaglobulinemia type 1, which is an immunodeficiency characterized by the failure to produce mature B lymphocytes, and associated with a failure of Ig heavy chain rearrangement.
Bruton agammaglobulinemia tyrosine kinase
, B-cell progenitor kinase
, agammaglobulinaemia tyrosine kinase
, dominant-negative kinase-deficient Brutons tyrosine kinase
, tyrosine-protein kinase BTK
, tyrosine-protein kinase BTK isoform (lacking exon 14)
, Bruton's tyrosine kinase
, Tyrosine-protein kinase BTK (Brutons tyrosine kinase) (Agammaglobulinaemia tyrosine kinase) (ATK) (B cell progenitor kinase) (BPK) (Kinase EMB)
, X-linked immune deficiency
, agammaglobulinemia tyrosine kinase
, bruton tyrosine kinase
, kinase EMB